Vascular Pattern Analysis for the Prediction of Clinical Behaviour in Pheochromocytomas and Paragangliomas by Oudijk, Lindsey et al.
Vascular Pattern Analysis for the Prediction of Clinical
Behaviour in Pheochromocytomas and Paragangliomas
Lindsey Oudijk, Francien Van Nederveen, Ce´cile Badoual, Fre´de´rique Tissier,
Arthur Tischler, Marcel Smid, Jose´ Gaal, Charlotte Lepoutre-Lussey,
Anne-Paule Gimenez-Roqueplo, Winand Dinjens, et al.
To cite this version:
Lindsey Oudijk, Francien Van Nederveen, Ce´cile Badoual, Fre´de´rique Tissier, Arthur Tischler,
et al.. Vascular Pattern Analysis for the Prediction of Clinical Behaviour in Pheochromocy-
tomas and Paragangliomas. PLoS ONE, Public Library of Science, 2015, 10 (3), pp.e0121361.
<10.1371/journal.pone.0121361>. <inserm-01142426>
HAL Id: inserm-01142426
http://www.hal.inserm.fr/inserm-01142426
Submitted on 15 Apr 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

RESEARCH ARTICLE
Vascular Pattern Analysis for the Prediction
of Clinical Behaviour in Pheochromocytomas
and Paragangliomas
Lindsey Oudijk1, Francien van Nederveen2☯, Cécile Badoual3,4☯, Frédérique Tissier5,6☯,
Arthur S. Tischler7☯, Marcel Smid8, José Gaal1, Charlotte Lepoutre-Lussey3,9, Anne-
Paule Gimenez-Roqueplo3,9,10, Winand N.M. Dinjens1, Esther Korpershoek1, Ronald de
Krijger1,11‡, Judith Favier3,9‡*
1 Department of Pathology, Erasmus MCCancer Institute, Erasmus MC, University Medical Center,
Rotterdam, the Netherlands, 2 Laboratory for Pathology, PAL Dordrecht, Dordrecht, the Netherlands,
3 Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, F-75006 Paris, France,
4 Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Département
d’anatomo-pathologie, F-75015 Paris, France, 5 Department of Pathology, Pitié-Salpetrière Hospital, AP-
HP, Pierre and Marie Curie University, Sorbonne Universities, Paris, France, 6 INSERMU1016 CNRS
UMR8104, Institut Cochin, Paris Descartes University, Sorbonne Paris Cité, France, 7 Department of
Pathology, Tufts University School of Medicine & Tufts Medical Center, Boston, Massachusetts, United
States of America, 8 Department of Medical Oncology, Erasmus MC Cancer Institute, Cancer Genomics
Netherlands, Rotterdam, The Netherlands, 9 INSERM, UMR970, Paris Cardiovascular Research Center, F-
75015 Paris, France, 10 Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges
Pompidou, Service de Génétique, F-75015 Paris, France, 11 Department of Pathology, Reinier de Graaf
Hospital, Delft, the Netherlands
☯ These authors contributed equally to this work.
‡ These authors are joint last authors on this work.
* judith.favier@inserm.fr
Abstract
Pheochromocytomas (PCCs) are neuroendocrine tumors arising from chromaffin cells of
the adrenal medulla. Related tumors that arise from the paraganglia outside the adrenal me-
dulla are called paragangliomas (PGLs). PCC/PGLs are usually benign, but approximately
17% of these tumors are malignant, as defined by the development of metastases. Current-
ly, there are no generally accepted markers for identifying a primary PCC or PGL as malig-
nant. In 2002, Favier et al. described the use of vascular architecture for the distinction
between benign and malignant primary PCC/PGLs. The aim of this study was to validate
the use of vascular pattern analysis as a test for malignancy in a large series of primary
PCC/PGLs. Six independent observers scored a series of 184 genetically well-character-
ized PCCs and PGLs for the CD34 immunolabeled vascular pattern and these findings
were correlated to the clinical outcome. Tumors were scored as malignant if an irregular
vascular pattern was observed, including vascular arcs, parallels and networks, while tu-
mors with a regular pattern of short straight capillaries were scored as benign. Mean sensi-
tivity and specificity of vascular architecture, as a predictor of malignancy was 59.7% and
72.9%, respectively. There was significant agreement between the 6 observers (mean κ =
0.796). Mean sensitivity of vascular pattern analysis was higher in tumors>5 cm (63.2%)
and in genotype cluster 2 tumors (100%). In conclusion, vascular pattern analysis cannot
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be used in a stand-alone manner as a prognostic tool for the distinction between benign and
malignant PCC, but could be used as an indicator of malignancy and might be a useful tool
in combination with other morphological characteristics.
Introduction
Pheochromocytomas (PCCs) are neuroendocrine tumors derived from chromaffin cells of the
adrenal medulla. Related tumors that arise from the paraganglia outside the adrenal medulla
are called paragangliomas (PGLs). Paragangliomas can be further classified as parasympathetic
or sympathetic, depending on their origin. Parasympathetic PGLs are mainly located in the
head and neck and usually do not secrete catecholamines, unlike PCCs and sympathetic PGLs
(located in the thorax, abdomen and pelvis) that usually produce adrenaline or noradrenaline.
[1] About 40% of PCCs and PGLs carry a germline mutation in one of the following genes:
SDHA, SDHB, SDHC, SDHD (referred to as SDHx), RET, VHL, NF1, TMEM127,MAX,
SDHAF2, and the recently identified gene FH (for review, see [2]). In addition, somatic muta-
tions of RET, VHL, NF1,MAX,HIF2A and HRAS can be detected in a further 25–30% of these
tumors.[3–6] SDHx and VHL-related PCC/PGL are referred to as ‘cluster 1’ tumors, following
microarray gene expression studies, while ‘cluster 2’ includes the tumors with RET, NF1,
TMEM127, andMAXmutations.[7,8]
Ten to 17% of PCCs and sympathetic PGLs are malignant, in which cases the prognosis of
patients is poor and treatment basically palliative. Malignancy in PCC/PGL is defined by the
2004 World Health Organization classification as a chromaffin cell tumor with the presence of
metastases to sites where chromaffin tissue should normally not be found (principally bones,
liver, lymph nodes and lungs).[9,10] This definition distinguishes malignancy from multifocal
disease. Local invasive growth of the tumor into other organs or major blood vessels, as has
been reported to predict malignant behavior in other tumor types, does not fulfill the definition
in PCC/PGL. The diagnosis of malignancy is clear-cut if metastatic lesions are present, but to
date, no molecular or histologic markers exist to predict if a primary PCC/PGL has metastatic
potential. Metastases can occur after a long latency period, sometimes more than 10 or even 20
years after diagnosis of the primary tumor.[11]
Currently, clinical risk factors for metastasis in patients with PCC/PGLs include tumor loca-
tion, genotype, and size.[12] Patients with SDHB-related PCC/PGLs, extra-adrenal tumors or a
primary tumor size over 5 cm have a higher risk to develop metastatic disease. In general, risk
is highest for SDHB-mutated tumors (at least 30%), which are usually extra-adrenal and rela-
tively large. Many studies have tried to find biomarkers to differentiate between benign and
malignant PCC/PGL, such as the Ki67 labeling index, human telomerase reverse transcriptase
(hTERT) or CD44 expression.[13,14] However, none of these markers allows a definite diagno-
sis of malignancy in PCC/PGL. Also, histologic criteria such as vascular invasion, mitotic activ-
ity, or cellular atypia cannot be used to definitely differentiate tumors with the potential to
metastasize. The Pheochromocytoma of the Adrenal gland Scaled Score (PASS) was the first
scoring system for the diagnosis of PCCs, which combined histopathological features to distin-
guish between benign and malignant tumors.[15] However, the reproducibility of the PASS
has not been established.[16] Recently, Kimura et al. proposed the combination of GAPP
(Grading of Adrenal Phaeochromocytoma and Paraganglioma) classification and SDHB
immunohistochemistry for the prediction of metastasis in PCCs.[17]
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PCCs and PGLs are highly vascularized tumors, even though there is a lot of variation in the
vascular architecture of individual tumors. In 2002, we described the use of the vascular archi-
tecture for the distinction between benign and malignant PCC/PGLs.[18] We observed that
malignant PCCs displayed a peculiar vascular pattern, which was not found in benign tumors.
However, this published series was small and therefore the vascular pattern analysis was not
implemented in routine PCC/PGL diagnostics. In the present study we determined, in a multi-
center international collaboration, the vascular pattern of 184 genetically well-characterized
PCCs and PGLs. The results of these analyses were correlated to the clinical behavior of the tu-
mors. This allows determining the role of vascular pattern analysis in the initial pathological
work-up of PCC and PGL patients.
Materials and Methods
We analyzed 88 paraffin-embedded tumors collected from 72 PCC/PGL patients collected
from the archives of the Department of Pathology of the Erasmus MC Cancer Institute, Eras-
mus MC, University Medical Center (Rotterdam, the Netherlands) and 96 tumors from 87 pa-
tients collected from Paris by the French COMETE network from patients operated in two
referral centers in Paris (Hôpital Européen Georges Pompidou and Hôpital Cochin).
The series comprised 59 malignant tumors and 125 benign samples. As defined by the
World Health Organization (WHO) in 2004 [19], and by the international guidelines of the
Endocrine Society [20] diagnosis of malignancy was based on the presence of a metastasis at
the site were chromaffin cells are usually absent. A summary of the clinicopathological charac-
teristics of the tumors is provided in Table 1. The Dutch tissues were used in accordance with
the code of conduct Proper Secondary Use of Human Tissue established by the Dutch Federa-
tion of Medical Scientific Societies (http://www.federa.org). The study obtained the institution-
al review board approval [Medical Ethical Committee from Erasmus MC University Medical
Center, Rotterdam, The Netherlands] and patients gave their informed written consent. For
French tissues, informed signed consent was obtained from each patient recruited by the
COMETE network, and the study was formally approved by an institutional review board
[Comité de Protection des Personnes (CPP) Ile de France III, June 2012].
Table 1. Clinicopathological characteristics.
Mutated gene No. of tumors Sex M/F Age range (yr; mean) PCC PGL Meta B/M Tumor size (mm; mean) FU (yr; mean)
VHL germline 20 13/7 7–50 (22.3) 16 4 0 17/3 25–80 (47.8) 9.2
VHL somatic 7 2/5 17–56 (37.1) 5 2 0 4/3 18–110 (62) 10.83 (N = 1D)
RET germline 24 4/20 16–76 (38.3) 24 0 0 24/0 9–110 (32.3) 9.97 (N = 1D)
RET somatic 2 1/1 49–62 (55.5) 2 0 0 2/0 NA 7.5
NF1 germline 13 4/8 (1U) 26–65 (40) 13 0 0 13/0 25–70 (48.3) 7.75
NF1 somatic 5 4/1 37–73 (49.6) 4 0 1 3/2 60–80 (38.3) 7.6
SDHA 2 1/1 32 1 1 0 2/0 60–72 (66) 0.5
SDHB 20 9/11 10–63 (36.6) 8 10 2 5/14 (1U) 40–140 (90.9) 9.83 (N = 4D)
SDHC 1 0/1 16 0 1 0 1/0 45 NA
SDHD 8 8/0 16–62 (36) 2 6 0 4/4 20–100 (51.3) 15.83
TMEM127 2 0/2 44 2 0 0 2/0 NA 15
HRAS somatic 1 0/1 61 1 0 0 1/0 NA 9 (D)
FH 1 0/1 63 0 0 1 0/1 40 10.5 (D)
SPOR 78 37/41 9–79 (48.6) 61 (2U) 10 5 46/32 7–130 (60.5) 7.20 (N = 1D)
M, male; F, female; U, unknown; PCC, pheochromocytoma; PGL, paraganglioma; Meta, metastasis; B, benign; M, malignant; FU, follow-up; D, died.
doi:10.1371/journal.pone.0121361.t001
Vascular Pattern in Paragangliomas
PLOS ONE | DOI:10.1371/journal.pone.0121361 March 20, 2015 3 / 10
Immunohistochemical analysis was performed by staining endothelial cells with CD34
monoclonal antibody on 4–6 μm sections of formalin-fixed paraffin-embedded tumors.
For French slides, the anti-CD34 (IM0786, Beckman Coulter) was used at a 1:500 dilution.
After deparaffinization, rehydration and H2O2 treatment, tissues were blocked in goat serum
for 30 minutes and the primary antibody was applied at room temperature for 1h. The biotiny-
lated secondary anti-rabbit antibody (Vector Lab; 1:400) was applied for 45 minutes and the
revelation was assessed using histogreen kit (Vector Laboratories, EUROBIO/ABCYS, Les Ulis,
France). Slides were counterstained with Nuclear Fast red and coverslipped.
For Dutch samples, a 1:75 dilution of the CD34 monoclonal antibody (clone QBEnd/10;
Neomarkers) was used, together with a protocol based on the Ventana BenchMark Ultra Sys-
tem (Ventana Medical Systems, Inc, Tucson, AZ). After deparaffinization, slides were submit-
ted to heat-induced epitope retrieval in Ventana Cell Conditioning 1 (pH 8.4) at 99°C for 64
minutes. Endogenous peroxidase was blocked using 3% hydrogen peroxide. The diluted CD34
antibody was applied and incubated for 32 minutes at 36°C. The stains were developed using
3,3'-diaminobenzidine (DAB) as chromogene. Finally, the slides were counterstained in hae-
matoxylin, washed in water, dehydrated through graded alcohol and coverslipped.
In all cases, negative control experiments were performed by omitting the primary
antibody.
Based on the results from the study by Favier et al., a tutorial (training set) with representa-
tive immunohistochemical images of vascular patterns related to benign and malignant tumors
(see S1–S4 Figs.) was distributed in advance among the 6 observers (1 research scientist (JF)
and 5 trained pathologists (CB, RK, FN, FT, AT)). After this, the immunohistochemical images
of the 184 tumors were independently evaluated by the 6 observers. All tumors had to be scored
into 4 groups according to their vascular architecture: benign (B+), probably benign (B-), prob-
ably malignant (M-) and malignant (M+).
Statistical analysis
To calculate the interobserver agreement the Kappa test was performed. The Chi-square test
was used to associate the prediction of the observers with clinicopathological characteristics of
the samples, i.e. clinical behavior, tumor size, genotype. Two-sided P values<0.05 were consid-
ered as statistically significant. Statistical tests were performed using Analyse-it v2.26 (Analyse-
it Software, Ltd. Leeds, United Kingdom).
Results
The vascular architecture of 184 PCC/PGL tumors was revealed by labeling endothelial cells
using CD34 immunohistochemistry. Tumors were blindly scored as “probably benign” (B-),
“certainly benign” (B+), “probably malignant” (M-), or “certainly malignant” (M+) according
to their vascular pattern by six expert pathologists. If the pattern was distributed regularly
throughout the whole tissue section, consisting mostly of short, straight vascular segments, tu-
mors were designated as benign. In contrast, if a discontinuous distribution of blood vessels
(i.e. highly vascularized zones adjacent to avascular areas) and vascular structures forming
arcs, parallels and networks could be identified, tumors were scored as malignant (Fig. 1 and
S2–S4 Figs.).
The interobserver agreement (Kappa agreement)
The interobserver agreements between all 6 observers after sorting the tumors into 4 groups
(B+, B-, M-, M+) ranged from a fair to moderate agreement (Table 2). The highest agreement
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was reached between observer 2 and 3 (κ = 0.596) and the lowest between observer 2 and 5
(κ = 0.351).
When the tumors were sorted into 2 groups (B+/- vs M+/-) the Kappa agreement was sub-
stantial to almost perfect (Table 3). Observer 1 and 4 displayed the highest agreement (κ =
0.897) and observer 2 and 5 the lowest ((κ = 0.725).
Vascular architecture as a prognostic tool
For each observer, the association between the predicted clinical outcome with the true benign
or malignant status of the tumor was investigated. The specificity of this approach, defined as
the percentage of benign cases correctly predicted as benign, ranged from 55.3%–79.8% (mean
72.9%). The sensitivity, defined as the percentage of malignant cases correctly predicted as ma-
lignant, ranged from 49.2%–71.9% (mean 59.7%). Observer 1 was the best predictor, with a
Youden index of 0.493 (Table 4).
Fig 1. Vascular architecture in PCC/PGLs. Immunostaining of blood vessels with anti-CD34 reveals a homogenously distributed vascular pattern in benign
tumors (A, D), while malignant tumors display irregularity (B) and vascular structures forming arcs (C), networks (E) and parallels (F). All panels are at the
samemagnification. Scale bar = 100μm.
doi:10.1371/journal.pone.0121361.g001
Table 2. Interobserver agreement (Kappa test) of benign, probably benign, probablymalignant andmalignant tumors (4 groups).
Observer 1 Observer 2 Observer 3 Observer 4 Observer 5
Observer 2 0.546
Observer 3 0.570 0.596
Observer 4 0.554 0.525 0.552
Observer 5 0.424 0.351 0.432 0.471
Observer 6 0.429 0.393 0.459 0.397 0.430
All agreements p<0.0001.
doi:10.1371/journal.pone.0121361.t002
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Overall, 35 of 59 (sensitivity is 59%) malignant PCCs were scored as malignant by the ma-
jority (i.e.4 of 6) of the observers. For benign tumors, there were 94 of 124 (specificity is
76%) tumors that were correctly predicted to be benign. In 13 benign tumors all observers
scored the tumor as malignant.
Taking tumor size into consideration, malignant tumors were significantly more often
greater than 5 cm compared to benign tumors (P = 0.0233). Mean sensitivity of vascular archi-
tecture as a prognostic tool in tumors>5 cm was 63.2% (range 50.0%–78.3%), while in smaller
tumors (<5 cm) the mean sensitivity was 57.5% (range 30.58%–76.8%). Mean specificity was
66.3% (range 50.0%–73.5%) and 80.8% (range 71.7%–85.7%) in tumors>5 cm and<5 cm,
respectively.
After splitting up the tumors according to genotype cluster (i.e. cluster 1: SDHx- and VHL-
related PCC/PGL; cluster 2: RET-, NF1-, and TMEM127-related tumors), malignant tumors
(n = 24) clustered more often in genotype cluster 1 (P<0.0001), compared to benign tumors
(n = 33). Mean sensitivity of vascular pattern analysis in genotype cluster 1 tumors was 52.3%
(range 33.3%–68.2%) and the mean specificity 69.1% (range 57.1%–78.8%). Mean sensitivity in
cluster 2 tumors (n = 52, of which 49 benign and 3 malignant) was 100% (range 100%–100%)
and the mean specificity 77.4% (range 57.58%–57.8%).
Discussion
Currently it is still not possible to state with certainty whether a primary PCC or PGL is benign
or malignant. The diagnosis of malignancy depends on the occurrence of metastases, which is
Table 3. Interobserver agreement (Kappa test) of (probably) benign versus (probably) malignant tumors (2 groups).
Observer 1 Observer 2 Observer 3 Observer 4 Observer 5
Observer 2 0.852
Observer 3 0.849 0.842
Observer 4 0.897 0.803 0.831
Observer 5 0.779 0.725 0.747 0.785
Observer 6 0.783 0.765 0.773 0.788 0.727
All agreements p<0.0001.
doi:10.1371/journal.pone.0121361.t003
Table 4. Associating predicted benign/malignant call with TRUE benign/malignant status.
Observer 1 Observer 2 Observer 3 Observer 4 Observer 5 Observer 6
Sensitivity 69.5% 50.8% 50.9% 66.1% 71.9% 49.2%
Speciﬁcity 79.8% 74.0% 74.1% 77.4% 55.3% 76.6%
PPV 62.1% 48.4% 48.3% 58.2% 44.6% 50.0%
NPV 84.6% 75.8% 76.1% 82.8% 79.7% 76.0%
Pval 8.3E-11 0.0009 0.0012 1.1E-08 0.0008 0.0005
Youden 0.493 0.248 0.250 0.435 0.272 0.258
Sensitivity is deﬁned as the percentage of TRUE malignant cases correctly predicted as malignant
Speciﬁcity is deﬁned as the percentage of TRUE benign cases correctly predicted as benign
Pval: p-value Chi-square test
PPV: positive predictive value
NPV: negative predictive value
Youden is deﬁned as sensitivity+speciﬁcity-1. The higher the Youden, the better the prediction.
doi:10.1371/journal.pone.0121361.t004
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rare and can have a latency of many years.[11] Considering the concept that induction of an-
giogenesis is necessary for tumor growth and metastases, and because PCCs are highly vascu-
larized tumors, we analyzed the vascular pattern of 184 PCC/PGL, immunohistochemically
stained with anti-CD34 antibody. Mean sensitivity and specificity of vascular architecture, as a
predictor of malignancy was 59.7% and 72.9%, respectively. There was significant agreement
between the 6 observers (mean κ = 0.796). Mean sensitivity of vascular pattern analysis was
higher in tumors>5 cm (63.2%) and in genotype cluster 2 tumors (100%).
The rationale of this study is based on a previous study where we observed an abnormal and
discontinuous vascular pattern, including vascular arcs, parallels and networks in 9 of 9 malig-
nant PCCs[18]. On the contrary, 9 of 10 benign tumors in that series showed a homogenous
pattern of short straight capillaries. The biological significance of these differences in vascular
pattern between benign and metastatic PCC/PGL is unclear. Whether the irregularity in the
vascular architecture of malignant tumors corresponds to different steps in the angiogenic pro-
cess or to a specific growth pattern of tumor cells is difficult to apprehend in the context of the
actual study. It may anyhow have an influence on the oxygenation status of tumor cells and
may reflect a capacity of malignant cells to resist to hypoxia. Since the initial cohort of 19 tu-
mors was small (and of incomplete genotyping, at that time), we validated vascular pattern
analysis in a larger cohort, fully characterized at the molecular level, and with multiple observ-
ers. In the current study, 35 of 59 (59%) malignant PCCs were scored as malignant by a majori-
ty of the observers. In contrast, 94 of 124 (76%) benign tumors were correctly predicted to be
benign. We could not confirm the high sensitivity of 100% using vascular pattern analysis for
the distinction between benign and malignant PCC, as reported in the initial study.
The Pheochromocytoma of the Adrenal gland Scaled score (PASS) was developed in 2002
by Thompson, to distinguish benign from malignant PCC by histopathological parameters.
[15] The following features (with values) were scored: large cell nests or diffuse growth (2), cen-
tral or confluent tumor necrosis (2), high cellularity (2), cellular monotony (2), tumor cell spin-
dling (2), mitotic figures more than 3 per 10 HPF (2), atypical mitotic figures (2), extension
into adipose tissue (2), vascular invasion (1), capsular invasion (1), profound nuclear pleomor-
phism (1) and nuclear hyperchromasia (1). Each histopathological feature of the PASS score
was given a value of 1 or 2 and these values are summed up. Of the 50 metastatic tumors inves-
tigated in that study, all had a PASS score of more than 4. However, the study also reported
that 17 of the 50 benign tumors had a score of more than 4 as well (with a follow-up period of 5
years).[15] Hence, an inappropriately high proportion of tumors were suggested to have malig-
nant potential. This overestimation of malignant tumors is something we also encountered in
the present study, although our specificity was higher (76% versus 66%).
Later, in a study by Wu et al. in 2009, five endocrine pathologists investigated the applicabil-
ity of the PASS and it showed a large inter- and intra-observer variation [16]. In contrast, we
found a substantial interobserver agreement (mean κ = 0.796) among 6 observers recognizing
vascular patterns, indicating that the vascular pattern classification system used in our study is
a much less complicated tool. However, because of low sensitivity and specificity the system is
unlikely to be useful for stratifying risk of metastasis. Despite this disappointing outcome, it is
of interest that several of the vascular patterns might actually provide means to enhance recog-
nition of histologic parameters scored in the PASS including diffuse growth (Fig. 1C and 1F)
and large cell nests (Fig. 1B). The latter are also a component of the risk stratification system
proposed by Kimura et al.[17]
Many studies have reported the evaluation of angiogenesis in PCC/PGL by examining the
microvascular density (MVD). Most of these studies suggest an increase in MVD in malignant
versus benign tumors.[21–24] However, the quantification of MVD appeared not to be a reli-
able predictor of malignancy, which is confirmed by other studies reporting the absence of a
Vascular Pattern in Paragangliomas
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statistical association between microvascular counts and malignancy.[25] MVD counting can
be based on the number, length or branching of the vessels, which will definitely influence the
results. To our knowledge, our initial study [18] and the present study are the only ones focus-
ing on the difference in vascular architecture between benign and malignant PCC/PGL, instead
of blood vessel counting.
Although the immunohistochemical stainings were performed in two different medical uni-
versity centers, there was no bias due to the origin of the section, which was also demonstrated
by the kappa test.
Twenty-four clinically benign tumors (corresponding to 23 patients) in the present series
were scored as malignant by4 observers (S1 Table). Metastasis can occur up to 20 or even 30
years after the occurrence of a primary pheochromocytoma. We have addressed whether the
follow-up was sufficient to clearly establish the benign status of these tumors. For eight tumors
(7 patients), we had no follow-up data (most corresponded to surgeries performed at least 25
years ago). One patient has died due to unrelated disease, and one (scored as malignant by 5
observers) actually became metastatic recently. For the 15 other patients, median follow-up
was of 10 ± 6.4 years (range 2.3–19). Hence, although the follow-up is quite important for
these patients, we cannot exclude that some of these patients will develop a metastatic form of
their disease in the future.
In particular, 13 benign PCCs of 12 patients were scored as malignant by all 6 observers, so
attention should be paid to the follow-up of these patients. The corresponding cases included 4
RET (2 germline and 1 somatic mutation), 2 VHL (1 germline and 1 somatic mutation) and 6
sporadic PCCs.
In summary, we tested vascular architecture as a prognostic tool in 184 PCC/PGL after
CD34 immunolabeling. Tumors were scored as malignant if a discontinuous vascular pattern
was observed, including vascular arcs, parallels and networks, while tumors with a uniform
pattern of short straight capillaries were scored as benign. There was significant agreement be-
tween observers, indicating that there is a real variance between the different vascular patterns.
However, the mean sensitivity, defined as the percentage of TRUE malignant cases correctly
predicted as malignant, was only 59.7%. Accordingly, vascular pattern analysis cannot be used
in a stand-alone manner as a prognostic tool for the distinction between benign and malignant
PCCs. However, understanding the mechanisms responsible for the development of different
patterns might provide new information on tumor biology and ultimately prove to have
clinical value.
Supporting Information
S1 Fig. Vascular architecture of the adrenal medulla. Pictures are shown at a 10X (A) and a
20X (B) magnification. Scale bars = 100μm.
(TIF)
S2 Fig. Vascular architecture in benign tumors. Typical vascular architecture of benign PCC/
PGLs are shown for a cluster 2 patient (A, B) and a cluster 1 patient (C, D). Pictures were taken
at a 10X (A, C) and a 20X (B, D) magnification. Scale bars = 100μm.
(TIF)
S3 Fig. Vascular architecture in malignant tumors. Typical vascular patterns seen in malig-
nant PCC/PGLs are shown for 5 different tumors. These examples illustrate the irregular pat-
tern (A, B), the presence of networks (C-F), arcs (G, H) and parallels (I, J). Pictures are shown
at a 10X (A, C, E, G, I) and a 20X (B, D, F, H, J) magnification. Scale bars = 100μm.
(TIF)
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S4 Fig. Typical example of classification. Patients were sorted in a blinded manner into 4
groups regarding to their vascular architecture revealed by CD34 immunostaining of endothe-
lial cells and considered as certainly benign (A), probably benign (B), probably malignant (C)
and certainly malignant (D). Scale bars = 100μm
(TIF)
S1 Table. Apparently benign tumors classified as malignant according to the vascular pat-
tern. Score attributed by each of the 6 observers: benign (B+), probably benign (B-), probably
malignant (M-) and malignant (M+). F-U (Follow-up).
(DOCX)
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